Search

Your search keyword '"Jaffe, Elaine S"' showing total 2,613 results

Search Constraints

Start Over You searched for: Author "Jaffe, Elaine S" Remove constraint Author: "Jaffe, Elaine S"
2,613 results on '"Jaffe, Elaine S"'

Search Results

1. Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma

2. Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms

3. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

4. Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients

5. Breast Implant Associated Anaplastic Large Cell Lymphoma: Evidence-Based Consensus Conference Statement From The American Association of Plastic Surgeons

7. How I Diagnose Angioimmunoblastic T-Cell Lymphoma

14. CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma

15. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial

16. List Of Contributors

17. Lymphomas

18. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

20. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

21. DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS

22. A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile

26. B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement

31. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases

34. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease

37. Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements

38. Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

40. Novel markers in pediatric-type follicular lymphoma

42. Viral, immunologic, and clinical features of primary effusion lymphoma

43. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma

44. Motive and opportunity: MYCrearrangements in high-grade B-cell lymphoma with MYCand BCL2rearrangements (an LLMPP study)

45. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

46. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations

47. POSTER: ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

48. ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

49. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Catalog

Books, media, physical & digital resources